Skip to main content

Table 2 Transplant outcomes

From: Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial

Parameter Low-risk arm (group C, N=105) High-risk arm
NAC prophylaxis cohort (group A, N=80) High-risk control cohort (group B, N=40)
Median days of neutrophil engraftment (range) 13 (11–42) 12 (11–14) 12 (11–14)
Median days of platelet engraftment (range) 13 (9–168) 13 (9–217) 13 (10–219)
Acute GVHD at day 100, %(95% CI) 17.4(10.0–29.8) 26.2(16.6–35.8) 25.3(11.3–39.3)
CMV reactivation at day 100, %(95% CI) 84.8(78.0–91.6) 87.5(80.1–94.9) 85.0(73.2–95.8)
EBV reactivation at day 100, % (95% CI) 15.4( 8.0–22.8) 11.3(3.9–18.7) 12.7(2.1–23.3)
1-year incidence of relapse, %(95% CI) 6.7(1.0–12.3) 5.2(0–11.2) 6.5(0–15.5)
1-year incidence of NRM, %(95% CI) 3.2(0–6.6) 9.1(1.1 17.1) 6.4(0–15.4)
1-year probability of LFS, %(95% CI) 90.1(83.3–96.9) 85.8(77.5 95.0) 87.0(74.6–99.4)
1-year probability of OS, %(95% CI) 95.7(91.5–100) 88.3(79.1–97.5) 89.8(78.4–100)
  1. There were no statistically significant differences in any of these transplant outcomes between the three groups
  2. Abbreviations: NAC N-acetyl-L-cysteine, GVHD graft-versus-host disease, CI confidential interval, CMV cytomegalovirus, EBV Epstein-Barr virus, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival